Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jan Lötvall

Brain Metastatic Cancer Cells Release microRNA-181c-containing Extracellular Vesicles Capable of Destructing Blood–brain Barrier

Nature Communications

English

Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial

English

Mesenchymal Stromal Cell-Derived Nanovesicles Ameliorate Bacterial Outer Membrane Vesicle-Induced Sepsis via IL-10

Stem Cell Research and Therapy

English

Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma

English

Crowdsourcing to Explore Views About Asthma Severity Among Asthma Experts

Clinical and Translational Allergy

English

Circulating Eosinophil Progenitors Express Major Trafficking Related Molecules and Are More Activated Compared to Mature Eosinophils in Patients With Asthma

Clinical and Translational Allergy

English

Distribution of Γδ and Other T-Lymphocyte Subsets in Patients With Chronic Obstructive Pulmonary Disease and Asthma

English

Efficacy and Safety of Fluticasone Furoate 100 Μg Once-Daily in Patients With Persistent Asthma: A 24-Week Placebo and Active-Controlled Randomised Trial

English

Comparison of Vilanterol, a Novel Long-Acting Beta2 Agonist, With Placebo and a Salmeterol Reference Arm in Asthma Uncontrolled by Inhaled Corticosteroids

Journal of Negative Results in BioMedicine

English

The Influence of Personality Traits and Beliefs About Medicines on Adherence to Asthma Treatment

Primary Care Respiratory Journal

2011

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jan Lötvall

Brain Metastatic Cancer Cells Release microRNA-181c-containing Extracellular Vesicles Capable of Destructing Blood–brain Barrier

Safety and Tolerability of the Novel Inhaled Corticosteroid Fluticasone Furoate in Combination With the Β2agonist Vilanterol Administered Once Daily for 52 Weeks in Patients ≥12 Years Old With Asthma: A Randomised Trial

Mesenchymal Stromal Cell-Derived Nanovesicles Ameliorate Bacterial Outer Membrane Vesicle-Induced Sepsis via IL-10

Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma

Crowdsourcing to Explore Views About Asthma Severity Among Asthma Experts

Circulating Eosinophil Progenitors Express Major Trafficking Related Molecules and Are More Activated Compared to Mature Eosinophils in Patients With Asthma

Distribution of Γδ and Other T-Lymphocyte Subsets in Patients With Chronic Obstructive Pulmonary Disease and Asthma

Efficacy and Safety of Fluticasone Furoate 100 Μg Once-Daily in Patients With Persistent Asthma: A 24-Week Placebo and Active-Controlled Randomised Trial

Comparison of Vilanterol, a Novel Long-Acting Beta2 Agonist, With Placebo and a Salmeterol Reference Arm in Asthma Uncontrolled by Inhaled Corticosteroids

The Influence of Personality Traits and Beliefs About Medicines on Adherence to Asthma Treatment